TY - JOUR
T1 - Decreasing rate and extent of lymph node staging in patients undergoing radical prostatectomy may undermine the rate of diagnosis of lymph node metastases in prostate cancer
AU - Abdollah, Firas
AU - Sun, Maxine
AU - Thuret, Rodolphe
AU - Budäus, Lars
AU - Jeldres, Claudio
AU - Graefen, Markus
AU - Briganti, Alberto
AU - Perrotte, Paul
AU - Rigatti, Patrizio
AU - Montorsi, Francesco
AU - Karakiewicz, Pierre I.
PY - 2010/12
Y1 - 2010/12
N2 - Background: At radical prostatectomy (RP), pelvic lymph node dissection (PLND) represents the most accurate staging procedure for the presence of lymph node (LN) metastases. Objective: We evaluated the rate of PLND use and its lymph node count (LNC) over the last two decades. We also tested the relationship between LNC and the rate of pN1 stage. Design, setting, and participants: Between 1988 and 2006, 130 080 RPs were recorded in 17 Surveillance Epidemiology and End Results registries. Measurements: The statistical significance of temporal trends was evaluated with the chi-square trend test. Separate univariable and multivariable regression analyses tested the relationship between predictors and two end points: (1) lack of LN staging (pNx) and (2) presence of LN metastases (pN1). Results and limitations: Stage pNx was recorded in 25.9% of patients, and pNx rate was higher in more contemporary years (30.1% in 2000-2006 vs 20.8% in 1988-1993; multivariable p <0.001). When PLND was performed, an average of 7.4 LNs (median: 6) were removed. The average LNC decreased from 12.0 nodes (median: 12) in 1988 to 6.0 nodes (median: 4) in 2006. Overall pN1 rate was 3.4% and decreased from 10.7% to 3.1% between 1988 and 2006 (p <0.001). LNC was an independent predictor of pN1 stage (multivariable p <0.001). Conclusions: An increasingly larger proportion of prostate cancer patients remain without LN staging at RP. Fewer LNs were removed at PLND over time, resulting in fewer patients diagnosed with pN1 stage at RP. The impact of this phenomenon on cancer control outcomes is still to be verified.
AB - Background: At radical prostatectomy (RP), pelvic lymph node dissection (PLND) represents the most accurate staging procedure for the presence of lymph node (LN) metastases. Objective: We evaluated the rate of PLND use and its lymph node count (LNC) over the last two decades. We also tested the relationship between LNC and the rate of pN1 stage. Design, setting, and participants: Between 1988 and 2006, 130 080 RPs were recorded in 17 Surveillance Epidemiology and End Results registries. Measurements: The statistical significance of temporal trends was evaluated with the chi-square trend test. Separate univariable and multivariable regression analyses tested the relationship between predictors and two end points: (1) lack of LN staging (pNx) and (2) presence of LN metastases (pN1). Results and limitations: Stage pNx was recorded in 25.9% of patients, and pNx rate was higher in more contemporary years (30.1% in 2000-2006 vs 20.8% in 1988-1993; multivariable p <0.001). When PLND was performed, an average of 7.4 LNs (median: 6) were removed. The average LNC decreased from 12.0 nodes (median: 12) in 1988 to 6.0 nodes (median: 4) in 2006. Overall pN1 rate was 3.4% and decreased from 10.7% to 3.1% between 1988 and 2006 (p <0.001). LNC was an independent predictor of pN1 stage (multivariable p <0.001). Conclusions: An increasingly larger proportion of prostate cancer patients remain without LN staging at RP. Fewer LNs were removed at PLND over time, resulting in fewer patients diagnosed with pN1 stage at RP. The impact of this phenomenon on cancer control outcomes is still to be verified.
KW - Lymph node excision/statistics and numerical data
KW - Lymphatic metastasis/diagnosis
KW - Prostatic neoplasm/pathology
KW - SEER program
UR - http://www.scopus.com/inward/record.url?scp=78049484268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78049484268&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2010.09.029
DO - 10.1016/j.eururo.2010.09.029
M3 - Article
C2 - 20932637
AN - SCOPUS:78049484268
VL - 58
SP - 882
EP - 892
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 6
ER -